CARLSMED
PublicCARLSMED is now publicly traded
The data on this page reflects CARLSMED's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 22, 2025
Last Round
Series C
Extension
Feb 1, 2025
Total Funding Raised
$207.5M
Company Overview
CARLSMED operates in Medical Devices and is based in Carlsbad, California. Its recorded funding history includes a Series C Extension round in February 2025.
Carlsmed is a healthcare technology company that develops spinal implant devices and medical systems aimed at enhancing surgical outcomes and reducing healthcare costs for spine surgery.
Sector
Medical Devices
Verticals
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
AI Layer
Application
CARLSMED Comparables
Compare CARLSMED with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Highridge Medical | 82% | |
| Alphatec Holdings Inc | 80% | |
| Medtronic | 78% |
For institutional investors. Book with your work email.
CARLSMED Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jul 22, 2025 | ||||
| Series C Extension | Feb 1, 2025 | ||||
| Series C | Mar 18, 2024 | ||||
| Series B | Apr 19, 2022 | ||||
| Series A | Dec 16, 2020 | ||||
Seed | Jun 23, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CARLSMED Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Vertical Group | Series B, Series A |
| B Capital Group | Series C |
| Device of Tomorrow Capital | Seed |
| Cove Fund | Seed, Series B, Series A |
| U.S. Venture Partners | Series C Extension, Series B, Series A, Series C |
| BofA Securities | IPO |
| B Capital Group | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueNov 11, 2026
Carlsmed, Inc. reports $21.6 million in revenue for Q3 '26, up from $13.1M a year earlier, according to an SEC filing in California on Nov 10th '26.
- has_revenue_increased_byNov 11, 2026
Carlsmed, Inc. puts revenue growth at over 56% at the midpoint of its $78 million-to-$80 million 2026 outlook versus full-year 2025.
- has_revenueNov 11, 2026
Carlsmed, Inc. reaffirms full-year 2026 revenue guidance of $74 million to $78M as Richard Heppenstall becomes chief financial officer on Sep 28th '26.
- has_revenueNov 11, 2026
Carlsmed, Inc. reports quarterly revenue of $18.9M on Aug 25th '26.
- launchesOct 14, 2026
Carlsmed, Inc. launches its aprevo(R) Lumbar Bi-lateral Posterior System commercially in the United States at the North American Spine Society's 41st Annual Meeting in Texas on Oct 14th '26, enabling a direct posterior approach for personalized spine fusion.
For institutional investors. Book with your work email.
CARLSMED Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.